| Similar Articles |
|---|
 |
Chemistry World
January 30, 2014
Phillip Broadwith |
AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India.   |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
The Motley Fool
July 27, 2007
Tom Taulli |
A New Phase for Phase Forward Phase Forward wins a multi-million dollar contract for its clinical trial software; this infusion of cash provides even more resources for pursuing more growth. |
Chemistry World
July 31, 2014
Phillip Broadwith |
AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments. |
Chemistry World
June 10, 2013
Phillip Broadwith |
AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
Chemistry World
May 7, 2013
Phillip Broadwith |
AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK. |
Chemistry World
March 26, 2014
Phillip Broadwith |
AstraZeneca boosts open innovation efforts Astrazeneca has launched a new web portal, bringing together new and existing open innovation programs. The aim is to make collaboration with academics, other companies, governments and non-government organizations easier. |
The Motley Fool
June 21, 2004
Brian Gorman |
Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings. |
Chemistry World
October 15, 2013
Dinsa Sachan |
Supreme court ruling brings clinical trials to a halt in India The fate of 162 global clinical trials hangs in the balance, as the top Indian court has asked the government to provide more details on their approval process before they can proceed. |
Chemistry World
January 25, 2013
Rajesh Parishwad |
Indian supreme court's anger over unregulated clinical trials The fledgling clinical trials industry in India has been hit by recent revelations of a lack of regulation. Now, the country's supreme court has criticized the body that oversees clinical trials for its inaction in the face of these unethical practices. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
Chemistry World
May 19, 2014
Phillip Broadwith |
AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'. |
Chemistry World
November 9, 2015
Phillip Broadwith |
AstraZeneca to buy ZS Pharma for ion-balance drugs AstraZeneca has agreed to buy US specialist drug company ZS Pharma for around $2.7 billion in an effort to bolster its drug pipeline. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion. |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
Chemistry World
December 5, 2013
Phillip Broadwith |
Merck KGaA snaps up electronic materials specialist The speciality chemicals arm of Merck KGaA has agreed to buy out AZ Electronic Materials for 1.6 billion pounds in cash. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
Chemistry World
May 28, 2014
Phillip Broadwith |
Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules. |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
The Motley Fool
February 1, 2008
Brian Lawler |
AstraZeneca's Trying to Get Healthier Big pharma AstraZeneca tries to get back on track by reducing costs. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
Chemistry World
October 1, 2012
Andrew Turley |
Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years. |
The Motley Fool
July 22, 2004
Charly Travers |
Patience With MedImmune While MedImmune has one of the top-selling biologic drugs in the industry, the growth in revenues and earnings is a bit sluggish for what many biotech investors are looking for. |
The Motley Fool
April 12, 2004
Charly Travers |
Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors. |
Chemistry World
September 3, 2014
Rajesh Parishwad |
Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
The Motley Fool
April 26, 2007
Brian Lawler |
AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: MedImmune Will the years ahead continue to be positive for the biopharma? Next year's guidance is for revenue to grow 15% over the $1.3 billion that is expected in 2006. Investors should watch to make sure this is possible. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
AskMen.com
Richard Stevens |
Participating In Clinical Trials Check out what participating in clinical trials involves and how you can join a study. You may even make some cash in the process. |
Chemistry World
April 3, 2014
Emma Stoye |
Pharma giants plan new public--private collaborations AstraZeneca will partner with the Medical Research Council, in its new Cambridge site, while the Wellcome Trust Genome Campus will host a new center for target validation studies, jointly founded with the European Bioinformatics Institute and GlaxoSmithKline. |
Chemistry World
August 3, 2015
Phillip Broadwith |
AstraZeneca sells off drugs to streamline portfolio Anglo-Swedish pharmaceutical firm AstraZeneca has agreed to sell the rights to two drugs that the company considers lie outside its strategic focus areas. |
